Serum Levels of Cyfra 21 in Patients with Benign and Malignant Salivary Gland Tumors

Overview

Journal Iran J Otorhinolaryngol

Publisher Mashhad University of Medical Sciences

Specialty Otorhinolaryngology

Date 2017 Aug 19

PMID 28819618

Authors

Naghmeh Jeiroodi

Seyed Mohammad-Javad Aslani

Bijan Khademi

Mahyar Malekzadeh

Zohreh Jaafari-Ashkavandi

Affiliations

Soon will be listed here.

Abstract

Introduction: Cyfra 21 is a serum-soluble fragment of cytokeratin19. Increased Cyfra 21 serum levels and their benefit as a tumor marker have been shown in some malignancies. This study aimed to evaluate the serum levels of Cyfra 21 in patients with benign and malignant salivary gland tumors.

Materials And Methods: In this cross-sectional study, the serum level of Cyfra 21 in 44 patients with malignant salivary gland tumors and 16 cases of pleomorphic adenoma were compared with 28 healthy controls using enzyme-linked immunosorbent assay (ELISA). Data were analyzed statistically using the Kruskal Wallis test, analysis of variance (ANOVA) and Spearman's correlation tests.

Results: Mean serum levels of Cyfra 21 were 0.135 ± 0.285 ng/ ml in the control group, 0.167 ± 0.142 ng/ ml in patients with pleomorphic adenoma and 1.059 ± 3.251 ng/ml in patients with malignant salivary gland tumors. There was no significant difference among groups. Cyfra 21 levels did not correlate with location of tumor, clinical stage or cigarette smoking.

Conclusion: Results of the present study showed no significant difference in Cyfra 21 serum level in salivary gland tumors compared with normal individuals. In addition, Cyfra 21 serum level was not sufficiently sensitive to function as a tumor marker in salivary gland tumors.

References

Pujol J, Molinier O, Ebert W, Daures J, Barlesi F, Buccheri G . CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer. 2004; 90(11):2097-105. PMC: 2409493. DOI: 10.1038/sj.bjc.6601851. View

Haug U, Rothenbacher D, Wente M, Seiler C, Stegmaier C, Brenner H . Tumour M2-PK as a stool marker for colorectal cancer: comparative analysis in a large sample of unselected older adults vs colorectal cancer patients. Br J Cancer. 2007; 96(9):1329-34. PMC: 2360192. DOI: 10.1038/sj.bjc.6603712. View

Doweck I, Barak M, Greenberg E, Uri N, Kellner J, Lurie M . Cyfra 21-1. A new potential tumor marker for squamous cell carcinoma of head and neck. Arch Otolaryngol Head Neck Surg. 1995; 121(2):177-81. DOI: 10.1001/archotol.1995.01890020039009. View

Okamura K, Takayama K, Izumi M, Harada T, Furuyama K, Nakanishi Y . Diagnostic value of CEA and CYFRA 21-1 tumor markers in primary lung cancer. Lung Cancer. 2013; 80(1):45-9. DOI: 10.1016/j.lungcan.2013.01.002. View

Mendenhall W, Amdur R, Palta J . Intensity-modulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol. 2006; 24(17):2618-23. DOI: 10.1200/JCO.2005.04.7225. View

Jaafari-Ashkavandi Z, Ashraf M, Moshaverinia M . Salivary gland tumors: a clinicopathologic study of 366 cases in southern Iran. Asian Pac J Cancer Prev. 2013; 14(1):27-30. DOI: 10.7314/apjcp.2013.14.1.27. View

Kosacka M, Jankowska R . Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer. Pol Arch Med Wewn. 2009; 119(1-2):33-7. View

Rajkumar K, Ramya R, Nandhini G, Rajashree P, Ramesh Kumar A, Anandan S . Salivary and serum level of CYFRA 21-1 in oral precancer and oral squamous cell carcinoma. Oral Dis. 2013; 21(1):90-6. DOI: 10.1111/odi.12216. View

Wieskopf B, Demangeat C, Purohit A, Stenger R, Gries P, Kreisman H . Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role. Chest. 1995; 108(1):163-9. DOI: 10.1378/chest.108.1.163. View

10.

Li X, Shi Z, Wang Y, Liu Y, Liu T . Immunohistochemical expression of cytokeratins in human salivary gland acinic cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120(2):248-57. DOI: 10.1016/j.oooo.2015.04.014. View

11.

Durnez A, Verslype C, Nevens F, Fevery J, Aerts R, Pirenne J . The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology. 2006; 49(2):138-51. DOI: 10.1111/j.1365-2559.2006.02468.x. View

12.

Loyola A, de Sousa S, Araujo N, Araujo V . Study of minor salivary gland mucoepidermoid carcinoma differentiation based on immunohistochemical expression of cytokeratins, vimentin and muscle-specific actin. Oral Oncol. 1998; 34(2):112-8. DOI: 10.1016/s1368-8375(97)00070-5. View

13.

Fukunaga Y, Bandoh S, Fujita J, Yang Y, Ueda Y, Hojo S . Expression of cytokeratin 8 in lung cancer cell lines and measurement of serum cytokeratin 8 in lung cancer patients. Lung Cancer. 2002; 38(1):31-8. DOI: 10.1016/s0169-5002(02)00109-5. View

14.

Altemani A, Martins M, Freitas L, Soares F, Araujo N, Araujo V . Carcinoma ex pleomorphic adenoma (CXPA): immunoprofile of the cells involved in carcinomatous progression. Histopathology. 2005; 46(6):635-41. DOI: 10.1111/j.1365-2559.2005.02157.x. View

15.

Bustin S, Gyselman V, Williams N, Dorudi S . Detection of cytokeratins 19/20 and guanylyl cyclase C in peripheral blood of colorectal cancer patients. Br J Cancer. 1999; 79(11-12):1813-20. PMC: 2362804. DOI: 10.1038/sj.bjc.6690289. View

16.

Wu H, Wang P, Yeh J, Chen Y, Yen M, Huang R . Serum cytokeratin-19 fragment (Cyfra 21-1) is a prognostic indicator for epithelial ovarian cancer. Taiwan J Obstet Gynecol. 2014; 53(1):30-4. DOI: 10.1016/j.tjog.2013.02.002. View

17.

Rastel D, Ramaioli A, Cornillie F, Thirion B . CYFRA 21-1, a sensitive and specific new tumour marker for squamous cell lung cancer. Report of the first European multicentre evaluation. CYFRA 21-1 Multicentre Study Group. Eur J Cancer. 1994; 30A(5):601-6. DOI: 10.1016/0959-8049(94)90528-2. View

18.

Cao X, Zhang L, Feng G, Yang J, Wang R, Li J . Preoperative Cyfra21-1 and SCC-Ag serum titers predict survival in patients with stage II esophageal squamous cell carcinoma. J Transl Med. 2012; 10:197. PMC: 3548759. DOI: 10.1186/1479-5876-10-197. View

19.

Doweck I, Barak M, Uri N, Greenberg E . The prognostic value of the tumour marker Cyfra 21-1 in carcinoma of head and neck and its role in early detection of recurrent disease. Br J Cancer. 2000; 83(12):1696-701. PMC: 2363457. DOI: 10.1054/bjoc.2000.1502. View

20.

Tsai S, Kao C, Wang S . Study of a new tumor marker, CYFRA 21-1, in squamous cell carcinoma of the cervix, and comparison with squamous cell carcinoma antigen. Neoplasma. 1996; 43(1):27-9. View